Taysha Gene Therapies (TSHA) Stock Overview
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TSHA Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Taysha Gene Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.34 |
| 52 Week High | US$7.30 |
| 52 Week Low | US$2.34 |
| Beta | 1.16 |
| 1 Month Change | 17.41% |
| 3 Month Change | 41.20% |
| 1 Year Change | 140.15% |
| 3 Year Change | 817.51% |
| 5 Year Change | -66.63% |
| Change since IPO | -73.65% |
Recent News & Updates
Narrative Update • Jul 09
TSHA: Pivotal Rett Trial Progress And Safety Profile Could Drive Upside
Taysha Gene Therapies' analyst fair value estimate moved from $7.00 to $10.00 as analysts factor in higher confidence around TSHA-102's competitive position, a derisked safety profile, and updated REVEAL data that they view as supportive of its potential as a leading Rett gene therapy candidate. Analyst Commentary Recent Street research on Taysha Gene Therapies highlights a cluster of higher fair value estimates and price targets tied to progress with TSHA-102 in Rett syndrome.Seeking Alpha • Jun 30
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential
Summary Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the 33% response threshold needed for regulatory submission. Alignment with the FDA on pivotal trial endpoints and interim analysis could enable an accelerated BLA submission in 1H 2027. Robust cash runway into 2028 and recent $200M raise support execution through key data and regulatory catalysts. Read the full article on Seeking AlphaRecent updates
Narrative Update • Jul 09
TSHA: Pivotal Rett Trial Progress And Safety Profile Could Drive Upside
Taysha Gene Therapies' analyst fair value estimate moved from $7.00 to $10.00 as analysts factor in higher confidence around TSHA-102's competitive position, a derisked safety profile, and updated REVEAL data that they view as supportive of its potential as a leading Rett gene therapy candidate. Analyst Commentary Recent Street research on Taysha Gene Therapies highlights a cluster of higher fair value estimates and price targets tied to progress with TSHA-102 in Rett syndrome.Seeking Alpha • Jun 30
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential
Summary Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the 33% response threshold needed for regulatory submission. Alignment with the FDA on pivotal trial endpoints and interim analysis could enable an accelerated BLA submission in 1H 2027. Robust cash runway into 2028 and recent $200M raise support execution through key data and regulatory catalysts. Read the full article on Seeking Alpha
Narrative Update • Jun 25
TSHA: Pivotal Rett Trial Progress And Clean Safety Profile Will Drive Future Upside
Analysts have nudged their price targets for Taysha Gene Therapies higher, with recent moves such as BMO to $14, BofA to $10, and Citizens to $11, citing derisked safety data and stronger TSHA-102 efficacy in Rett syndrome as key supports for the revised valuation outlook. Analyst Commentary Recent research updates around Taysha Gene Therapies focus heavily on TSHA-102 in Rett syndrome and how new REVEAL data feeds into valuation, probability of success, and the overall risk profile for the stock.Narrative Update • Jun 07
TSHA: Lower Discount Rate And Higher Margin Assumptions Will Support Future Upside
Narrative Update on Taysha Gene Therapies The analyst price target for Taysha Gene Therapies has been raised by $3, with analysts pointing to slightly lower discount rate assumptions, a modestly higher projected profit margin, and a marginally reduced future P/E multiple as the key drivers of this adjustment. What's in the News The referenced sources did not include any recent news stories, periodical coverage, or key developments for Taysha Gene Therapies.Narrative Update • May 22
TSHA: Higher Margin Assumptions And Lower P/E Multiple May Support Future Upside
Analysts lifted their price target on Taysha Gene Therapies by about $0.66 to roughly $12.23 per share, citing updated assumptions around revenue growth, profit margin, and future P/E that they view as better aligned with the company’s current outlook. Analyst Commentary Recent research coverage around the updated price target focuses on how current assumptions for revenue growth, profitability, and future P/E tie back to both the opportunity and execution risks for Taysha Gene Therapies.Narrative Update • May 03
TSHA: Updated Margin And P/E Assumptions Will Support Future Upside Potential
Analysts have raised their price target on Taysha Gene Therapies by $3, citing updated assumptions around discount rates, margin expectations, and future P/E multiples as key drivers behind the revision. Analyst Commentary Recent commentary around the new price target focuses on how updated discount rates, margin assumptions, and future P/E multiples feed through to Taysha Gene Therapies' risk and reward profile.Narrative Update • Apr 19
TSHA: Rett Pivotal Trial Progress And FDA Alignment Will Support Future Upside
Analysts have increased their price target on Taysha Gene Therapies by $3, citing updated views on the discount rate, profit margin, and future P/E assumptions as the key drivers of the change. Analyst Commentary Bullish Takeaways Bullish analysts view the revised discount rate as better aligned with the company’s current risk profile, which they see as supportive of a higher valuation framework.Narrative Update • Apr 05
TSHA: Rett Pivotal Trial Progress And FDA Alignment Will Drive Future Upside
Analysts have raised their price target on Taysha Gene Therapies to about $11.57 from roughly $11.29, reflecting small shifts in assumptions around risk, revenue growth, profit margins and future P/E expectations. What's in the News Taysha Gene Therapies reported progress across its TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy in clinical evaluation for the treatment of Rett syndrome (Key Developments).Narrative Update • Mar 21
TSHA: Rett Gene Therapy Trials And FDA Alignment Will Drive Future Upside
Analysts have modestly raised their price target for Taysha Gene Therapies from $11.00 to about $11.29, reflecting revised assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News Taysha Gene Therapies reported progress across its TSHA-102 pivotal program, an intrathecal AAV9 gene therapy in clinical evaluation for Rett syndrome treatment (Key Developments).Narrative Update • Mar 06
TSHA: Rett Pivotal Trial Progress And FDA Alignment Will Drive Upside
Analysts have reaffirmed their $11.00 price target for Taysha Gene Therapies, with small adjustments to assumptions such as discount rate, profit margin, and future P/E guiding the updated view. What's in the News Taysha Gene Therapies reported progress across its TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy in clinical evaluation for the treatment of Rett syndrome (Key Developments).Narrative Update • Feb 20
TSHA: Rett Pivotal Progress And FDA Alignment Will Drive Future Upside
Analysts are maintaining their price target for Taysha Gene Therapies at $11.00, making only a slight adjustment to their model inputs as they balance a lower discount rate and modestly lower profit margin expectations against a slightly higher assumed future P/E multiple. What's in the News Taysha Gene Therapies reported progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy in clinical evaluation for the treatment of Rett syndrome (Key Developments).Narrative Update • Feb 05
TSHA: REVEAL Safety Alignment And Raised Expectations Will Drive Rett Upside
Analysts recently lifted their price target on Taysha Gene Therapies to $19 from $13, citing updated views that are reflected in only minor shifts to assumptions such as discount rate and future P/E, while keeping fair value estimates broadly unchanged. Analyst Commentary Recent research points to a higher price target of $19, up from $13, with only modest tweaks to inputs such as discount rate and future P/E, and with fair value estimates broadly steady.Narrative Update • Jan 22
TSHA: REVEAL Safety Data And Finalized Plan Will Drive Rett Upside
Analysts have nudged their price targets higher on Taysha Gene Therapies, with recent moves such as US$13 to US$19 and US$6 to US$8 reflecting increased confidence in the REVEAL program and its finalized statistical analysis plan. This feeds into our modest fair value adjustment from US$10.79 to about US$11.00.Narrative Update • Jan 06
TSHA: REVEAL Trial Progress And FDA Feedback Will Drive Rett Therapy Leadership
Analysts have nudged their fair value estimate for Taysha Gene Therapies higher to about $10.79 per share, up from roughly $10.57. This adjustment reflects a series of recent price target increases across the Street that cite REVEAL trial data, regulatory feedback, and perceived competitive positioning in Rett syndrome as key supports.Narrative Update • Dec 16
TSHA: Breakthrough Therapy Designation Will Drive Future Rett Gene Therapy Leadership
The analyst price target for Taysha Gene Therapies has moved modestly higher to approximately $10.57 from about $10.54, reflecting analysts' increased confidence in TSHA-102's breakthrough designation, regulatory alignment, and supportive pivotal trial data from the REVEAL program. Analyst Commentary Street research remains broadly constructive on Taysha Gene Therapies, with multiple firms lifting price targets in response to recent clinical, regulatory, and strategic milestones around TSHA-102 in Rett syndrome.Narrative Update • Nov 30
TSHA: Breakthrough Therapy Designation And FDA Alignment Will Drive Momentum In Rett Program
Analysts have raised their price target for Taysha Gene Therapies by nearly $0.50 to approximately $10.54. This reflects improved confidence in the company's clinical progress and regulatory milestones, particularly for its Rett syndrome program.Narrative Update • Nov 16
TSHA: Breakthrough Therapy Designation Will Accelerate Momentum In Rett Syndrome Trials
Taysha Gene Therapies' analyst price target has been increased from approximately $9.77 to $10.08. Analysts cite advancing clinical milestones, favorable FDA feedback, and increased confidence in the company's path forward for its Rett syndrome gene therapy program as key drivers for the upward revision.Narrative Update • Nov 01
TSHA: Recent Breakthrough Therapy Designation Will Accelerate Approval In Rett Syndrome
The analyst consensus price target for Taysha Gene Therapies has increased slightly from $9.50 to approximately $9.77, as analysts cite recent positive clinical milestone achievements, favorable FDA feedback, and an improved outlook for TSHA-102 in Rett syndrome. Analyst Commentary Bullish analysts remain highly positive on Taysha Gene Therapies following a series of milestone achievements and regulatory developments.Narrative Update • Oct 17
FDA Meetings And TSHA-102 Trials Will Advance Approval
Analysts have increased their average price target for Taysha Gene Therapies to $9.50, up slightly from $9.42. Multiple firms cited the recent FDA breakthrough designation for TSHA-102, progress in pivotal trials, and perceived derisking of the program as key drivers of their positive outlook.Narrative Update • Oct 03
FDA Meetings And TSHA-102 Trials Will Advance Approval
Taysha Gene Therapies’ analyst price target has increased from $8.32 to $9.42. Analysts point to recent FDA breakthrough therapy designation and progress in clinical studies as key drivers of heightened expectations.
New Narrative • Mar 31
FDA Meetings And TSHA-102 Trials Will Advance Approval
Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence.Seeking Alpha • Jan 28
Taysha Gene Therapies Is Showing Promise For Rett Syndrome
Summary Taysha Gene Therapies' TSHA-102 tackles Rett syndrome’s root cause with its miniMECP2 transgene and scAAV delivery. So far, this is TSHA’s main value driver, and it appears safe and effective in both of its trial’s high and low-dose cohorts. TSHA-102 has an RMAT designation, which could accelerate its approval process. Management anticipates a regulatory submission by 2H2025. The company's cash runway seems safe into late 2026, and its valuation is in line with peers. There are multiple catalysts in 2025 as well. I reiterate my “Buy” rating for TSHA stock. Read the full article on Seeking AlphaSeeking Alpha • Oct 14
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Summary Taysha Gene Therapies' TSHA-102 shows promising results for Rett syndrome, leveraging miRARE technology to modulate MECP2 expression, improving patients' quality of life in Phase 1/2 trials. TSHA-102's unique miRNA-responsive auto-regulatory feature ensures safe MECP2 levels, with intrathecal administration targeting CNS cells, minimizing systemic adverse effects. Despite recent stock price decline, TSHA has a solid cash runway and potential market, with key catalysts expected by late 2024 and 1H2025. Regulatory designations like RMAT and Orphan Drug status may expedite TSHA-102's approval process, enhancing its market potential. I reiterate my "Buy" rating for TSHA due to its focused R&D, promising early data, and potential significant upside if higher dose trials confirm safety and effectiveness. Read the full article on Seeking AlphaAnalysis Article • Jun 27
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%
Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) shares have had a horrible month, losing 37% after a relatively good period...Seeking Alpha • Jun 20
Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
Summary Taysha Gene Therapies stock fell over 25% after disappointing data from Phase 1/2 REVEAL study of TSHA-102 in Rett Syndrome patients. TSHA-102 is a gene therapy targeting Rett Syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies. Despite some positive signs in initial data, the lack of a placebo arm and the need for more data to support approval are evident, given the recent approval of Dayvue. Taysha has limited funding and no other assets to fall back on should TSHA-102 not succeed - the risk of further losses is therefore significant. Read the full article on Seeking AlphaAnalysis Article • Apr 20
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) shareholders will have a reason to smile today, with the analysts making...Shareholder Returns
| TSHA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | 0.02% | 0.6% |
| 1Y | 140.2% | 36.1% | 19.5% |
Return vs Industry: TSHA exceeded the US Biotechs industry which returned 36.1% over the past year.
Return vs Market: TSHA exceeded the US Market which returned 19.5% over the past year.
Price Volatility
| TSHA volatility | |
|---|---|
| TSHA Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TSHA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TSHA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 99 | Sean Nolan | www.tayshagtx.com |
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. Fundamentals Summary
| TSHA fundamental statistics | |
|---|---|
| Market cap | US$2.10b |
| Earnings (TTM) | -US$129.88m |
| Revenue (TTM) | US$7.47m |
271.4x
P/S Ratio-15.6x
P/E RatioIs TSHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSHA income statement (TTM) | |
|---|---|
| Revenue | US$7.47m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.47m |
| Other Expenses | US$137.35m |
| Earnings | -US$129.88m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,738.40% |
| Debt/Equity Ratio | 23.1% |
How did TSHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 22:04 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Taysha Gene Therapies, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Keith Tapper | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |